Castle Biosciences

244 articles with Castle Biosciences

• New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test

  5/5/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented data on its 15-gene expression profile (15-GEP) test, DecisionDx®-UM, at the Association for Research in Vision and Ophthalmology (ARVO) 2021: Revolutionary Eye and Vision Research Meeting.

• Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.

  5/4/2021

  Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, is a national sponsor of the Colorado Melanoma Foundation, a non-profit organization. Castle will collaborate with the Colorado Melanoma Foundation and Epiphany Dermatology to provide free skin cancer screenings and public education through the Sun Bus initiative.

• Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month

  4/30/2021

  Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike! ™ " Steps Challenge for Skin Cancer Awareness Month The month-long fundraising event invites the public to help log 9,500 miles in honor of the approximately 9,500 people diagnosed with skin cancer every day

• Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory

  4/27/2021

  Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath ® Laboratory With the acquisition, Castle expects to make available the most comprehensive molecular testing offering for difficult-to-diagnose melanocytic lesions. The Company to host a conference call today at 7:30 a.m. E.T.

• Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

  4/27/2021

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that it has signed a definitive agreement to sell the Myriad myPath Melanoma, LLC, Laboratory, which is the laboratory that offers the myPath Melanoma test, to Castle Biosciences for $32.5 million in cash.

• Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021

  4/26/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the first quarter 2021 and provide a pipeline update, after the close of market on Monday, May 10, 2021.

• Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population

  4/23/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, will present data at the American Academy of Dermatology’s Virtual Meeting Experience, being held April 23 – 25, 2021.

• Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention

  4/22/2021

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced participation in the Dermatology Nurses’ Association 2021 Annual Convention.

• Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress

  4/16/2021

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress.

• Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma

  4/15/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP) at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology (EADO) Congress.

• Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy

  4/14/2021

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced data from an independent, prospective study published in the American Journal of Surgery demonstrating DecisionDx®-Melanoma’s utility for prediction of outcomes in patients with cutaneous melanoma.

• Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx®-Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma

  4/13/2021

  Castle Biosciences Announces Prospective, Multi-Center Publication Demonstrating DecisionDx ® -Melanoma as Significant, Independent Predictor of Patient Outcomes in Cutaneous Melanoma Study published in JCO Precision Oncology

• Castle Biosciences Collaborates with the Melanoma Research Foundation for “Ask the Expert” Live Webinar Series with Melanoma Experts

  4/1/2021

  Castle Biosciences , Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webinar series, throughout the month of April.

• Castle Biosciences to Present at the 20th Annual Needham Virtual Healthcare Conference

  3/29/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 4:30 p.m. Eastern time.

• Castle Biosciences Announces Publication Demonstrating Dermatologists Are Increasingly Integrating DecisionDx-Melanoma Into Melanoma Clinical Management Decisions

  3/25/2021

  Cross-Sectional Study of 589 U.S. Dermatological Clinicians Demonstrating Clinical Utility Was Recently Published in SKIN: The Journal of Cutaneous Medicine

• Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk

  3/8/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that DecisionDx®-Melanoma, Castle’s prognostic gene expression profile test for cutaneous melanoma, now utilizes an Integrated Test Result (ITR)

• Castle Biosciences to Present at Upcoming Investor Conferences - Feb 08, 2021

  2/8/2021

  Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the following upcoming investor conferences:

• Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19th Annual South Beach Symposium

  2/4/2021

  Castle Biosciences Presents New Data on the Validity and Accuracy of DecisionDx-Melanoma in Patients With T1 Cutaneous Melanoma Tumors at the 19 th Annual South Beach Symposium Additional Virtual Posters Highlight Data on DecisionDx® DiffDx™-Melanoma and DecisionDx®-SCC

• Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Conference

  1/20/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced poster presentations with data on two of its skin cancer gene expression profile tests at the 18th Annual Winter Clinical Dermatology Conference, taking place virtually from Jan. 15 – 24, 2021.

• Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2020 Results

  1/13/2021

  Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.